Advertisement
Advertisement

LENZ

LENZ logo

LENZ Therapeutics Inc.

31.20
USD
-1.21
-3.73%
Dec 18, 15:25 UTC -5
Open

LENZ Therapeutics Inc. Profile

About

Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical trials for the treatment of presbyopia. Lenz Therapeutics Inc., formerly known as Graphite Bio Inc., is based in SOUTH SAN FRANCISCO, Calif.

Info & Links

CEO

Kimberlee C. Drapkin

Headquarters

611 Gateway Blvd, Suite 120
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Industry

Biotechnology

Sector

Health Technology

Website

www.graphitebio.com

Auditor

Deloitte & Touche LLP

Share holders

17

Employees

6

LENZ Therapeutics Inc. Statistics

Valuation Measures

Market Capitalization2

858M

Enterprise Value

816.84M

Enterprise Value/EBITDA(ttm)

-6.32

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

3.96

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-58.48%

Return on Invested Capital(ttm)

66.07%

Return on Assets(ttm)

-55.50%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-129.21M

Net Income Available to Common(ttm)

-115.49M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

0.52

52-Week Change

189.14%

S&P 500 52-Week Change

25.72%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

27.50M

Dividend Yield

0.00%

Float4

16.94M

% Held by Insiders

38.40%

% Held by Institutions

54.32%

Balance Sheet

Total Cash(mrq)

217.22M

Total Cash Per Share(mrq)

7.90

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

28.63%

Quick Ratio(mrq)

28.63%

Book Value Per Share(mrq)

7.83

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.85

Free Cash Flow(ytd)

-50.63M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement